Gastroesophageal junction adenocarcinoma

Researchers are testing whether adding zolbetuximab to standard chemotherapy is safe and helps control advanced stomach or gastroesophageal junction cancer in Indian patients. The trial enrolls 50 adults whose tumors carry the Claudin 18.2 protein but not HER2. Participants recei…

Researchers are testing whether combining an experimental dual immunotherapy drug called QL1706 with standard chemotherapy (docetaxel, oxaliplatin and S-1) before surgery can help patients with locally advanced gastric or gastroesophageal junction cancer. The study enrolls 34 adu…

Researchers are testing whether combining trastuzumab with retlirafusp alfa helps people with HER2-positive gastric or gastroesophageal junction cancer that has worsened after standard first-line treatment. The trial enrolls about 35 adults whose tumors test HER2 2+ or 3+. Partic…

Researchers are testing whether adding an experimental drug called ONO-4578 to nivolumab and chemotherapy helps people with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal adenocarcinoma. The trial enrolls about 600 adults whose tumors are HE…

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This trial tests whether pembrolizumab, an immunotherapy drug, is safe when combined with chemotherapy or chemoradiotherapy for people in India with advanced gastric or gastroesophageal junction cancer, advanced biliary tract cancer, or high-risk locally advanced cervical cancer.…

This trial tests whether combining two targeted therapies, with or without chemotherapy, can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. Participants receive the treatment before and after surgery to remove the tumor. The main goal is …

This trial tests whether an experimental drug called ATG-022 can slow the growth of advanced stomach or gastroesophageal junction cancer better than standard chemotherapy. The study enrolls adults whose tumors show a specific marker called CLDN18.2 and who have already tried at l…

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This Phase 2 trial is testing whether rilvegostomig, an experimental immunotherapy that blocks two immune-suppressing pathways (PD-1 and TIGIT), can produce a stronger immune response against advanced gastric cancer than the standard single-target drug pembrolizumab. About 50 peo…

This trial is testing whether adding the immunotherapy drug serplulimab to a standard chemotherapy regimen (SOX) after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. The study includes adults with stage II-III cancer whose tumors show certa…

This trial tests whether a home-based prehabilitation program, supported by 5G and artificial intelligence, can help gastric cancer patients prepare for surgery after chemotherapy. The program includes personalized exercise, nutrition, and psychological support, all supervised re…

This phase 2 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT before surgery, TS-1 after) can improve outcomes for people with resectable gastric or gastroesophageal junction cancer. The study aims to see if this combination increas…

This study looks at a new treatment for people with a specific type of advanced stomach cancer (HER2-positive) that has stopped responding to standard therapies. It combines a targeted drug (disitamab vedotin) with immunotherapy and a special type of radiation. The goal is to see…

This early-stage trial is testing an experimental treatment called the IKS04 regimen in people with advanced cancers of the digestive system, including colorectal, stomach, pancreatic, and bile duct cancers. The regimen combines a targeted antibody-drug conjugate with an addition…

This trial is investigating whether adding the beta-blocker propranolol to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with resectable locally advanced gastric or gastroesophageal junction cancer. About 49 participants will receive the c…

This phase II trial tests whether adding an immunotherapy drug (retlirafusp alfa) and possibly a third drug (pertuzumab) to the targeted therapy trastuzumab rezetecan can completely eliminate tumors before surgery in people with locally advanced HER2-positive stomach or gastroeso…

This Phase 3 trial tests whether an experimental drug called QLS31905, combined with chemotherapy (CAPOX), works better than the current immunotherapy drug sintilimab plus the same chemotherapy for people with advanced gastric or gastroesophageal junction cancer. The study includ…

This early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…

This study tests whether adding an experimental drug called retlirafusp alfa to standard chemotherapy can shrink advanced stomach or gastroesophageal junction cancers enough to allow complete surgical removal. Participants receive the drug combination before surgery, and those wh…

This phase II trial tests a combination of two drugs—sacituzumab tirumotecan (a targeted chemotherapy) and tagitanlimab (an immunotherapy)—as a second-line treatment for people with advanced esophageal squamous cell carcinoma or gastric/gastroesophageal junction adenocarcinoma. T…

This phase 3 trial tests whether adding an experimental drug called cadonilimab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. Cadonilimab is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) …

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This phase 2 trial tests a combination of two drugs—becotatugvedotin (a targeted therapy that delivers a toxin directly to cancer cells) and pucotenlimab (an immunotherapy that helps the immune system attack cancer)—as a second-line treatment for people with advanced gastric or g…

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan (Sac-TMT) and fruquintinib—as a second-line treatment for people with advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after initial therapy. The study enrolls about 45 par…

This study tests a new approach for people with locally advanced stomach cancer that has not spread to other organs. First, patients receive heated chemotherapy directly into the abdomen to kill any hidden cancer cells. Then they get an immunotherapy drug (serplulimab) combined w…

This trial investigates whether adding the targeted antibody zanidatamab to standard chemotherapy can shrink HER2-positive stomach or gastroesophageal junction cancers before surgery. It includes two groups: people with locally advanced cancer that has not spread, and those with …

This study tests a new biologic drug called HCB101 in combination with other cancer drugs (zolbetuximab and chemotherapy) for people with advanced gastric or gastro-esophageal cancer. The goal is to find a safe dose and see if the combination can shrink tumors. About 40 adults wi…

This phase 3 trial compares a new drug called Retlirafusp alfa plus chemotherapy against standard immunotherapy plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread to the liver and has not been treated before. The study aims to s…

This study investigates whether adding a short course of radiotherapy before surgery, alongside a PD-1 inhibitor (serplulimab) and chemotherapy (SOX), can improve outcomes for people with locally advanced upper stomach or gastroesophageal junction cancer. Participants are randoml…

This phase 2 trial tests a combination of three drugs—sintilimab, ramucirumab, and paclitaxel—in 30 adults with HER2-negative stomach cancer that came back during or within 6 months of finishing adjuvant therapy. The main goal is to see how many patients' tumors shrink significan…

This phase 2 trial tests whether adding the targeted drug fruquintinib to standard immunotherapy (sintilimab) and chemotherapy (SOX) can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 120 participants will receive either the t…

This phase 2 trial tests a combination of four drugs—mannatide, two chemotherapy drugs, and an immunotherapy—as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has spread or come back. The study will enroll 52 participants to see if the…

This study tests whether a simple blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide which stomach cancer patients need extra chemotherapy after surgery. About 304 people with locally advanced stomach cancer will be randomly assigned to either standard…

This study tests whether injecting a virus called RP2 directly into stomach and esophageal tumors, combined with standard FLOT chemotherapy, is safe and works better than chemotherapy alone before surgery. About 34 people with stage II or higher non-metastatic gastroesophageal ca…

This phase 2 trial tests whether adding a cholesterol-lowering drug (Tafolecimab) to standard immunotherapy (Sintilimab) and chemotherapy (SOX) can shrink tumors in 30 people with advanced pMMR/MSS gastric cancer, a type that usually doesn't respond well to immunotherapy alone. T…

This phase 2 trial tests a combination of three drugs—retlirafusp alfa, apatinib, and nab-paclitaxel—in 50 adults with advanced stomach or gastroesophageal junction cancer that has progressed after first-line immunotherapy. The goal is to see if the combination can shrink tumors …

This phase 2 trial is testing whether adding an experimental immunotherapy drug (SHR-1701) to standard chemotherapy can improve outcomes for people with a specific type of esophageal cancer (Siewert type II) that can be surgically removed. About 38 participants will receive the d…

This study tests a new drug combination (SKB315 plus an immunotherapy) in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 80 participants in China will receive the treatment to see if it shrinks tumors. The goal is to cont…

This study looks at whether changing the type of chemotherapy after stomach cancer surgery can help people live longer. It involves 405 adults who had chemotherapy and immunotherapy before surgery. Depending on how much cancer remained after surgery, some will get a different tre…

This early-phase trial is testing a combination of two drugs—trastuzumab rezetecan and retlirafusp alfa—in 12 people with HER2-positive stomach or gastroesophageal junction cancer. The treatment is given before surgery to see if it can safely shrink tumors. The main focus is on s…

This early-phase trial tests whether adding the experimental drug futibatinib to standard chemotherapy (paclitaxel) and an antibody (ramucirumab) is safe for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. The study…

This early-phase trial is testing a new treatment called CT0494BCP CAR-T cells in 50 adults with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified in a lab to bette…

This phase 2 trial tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemoradiotherapy can help people with locally advanced esophageal cancer whose initial chemo-immunotherapy did not work. About 40 participants will receive the treatment…

This study tests a combination of three drugs (sintilimab, bevacizumab, and chemotherapy) in people with a rare and aggressive type of stomach cancer that produces a protein called AFP. The goal is to shrink the tumors enough so they can be surgically removed. About 46 adults wit…

This study tests giving a combination of chemotherapy (FLOT) and an immunotherapy drug (durvalumab) before surgery, followed by more durvalumab after surgery, for people with stomach or esophageal cancer that can be removed. The goal is to see if this approach leads to a complete…

This clinical trial is testing a new approach for people with advanced HER2-negative stomach or gastroesophageal junction cancer that cannot be removed by surgery. The treatment combines two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (SOX) and a…

This early-phase trial tests whether adding an experimental immunotherapy drug (Retlirafusp alfa) to standard chemotherapy can improve outcomes for people with gastroesophageal junction adenocarcinoma. About 30 patients will receive the drug combination before surgery, and some m…

This study compares two ways of giving the immunotherapy drug AK104 alongside standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. One group gets AK104 as a shot under the skin (subcutaneous), the other as a…

This phase 3 trial will compare two surgical techniques for esophageal cancer: totally minimally invasive esophagectomy (TMIE) using only keyhole incisions, versus a hybrid approach that combines keyhole and open chest surgery. The study aims to see if TMIE reduces severe complic…

This phase II trial tests whether adding low-dose radiotherapy and the immunotherapy drug tislelizumab to standard chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 participants will be randomly assigned to r…

This early-stage study tests a new treatment called IM96 CAR-T for people with advanced stomach or esophageal cancer that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to better attack cancer cells. The main goal is to check saf…

This Phase II trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706) plus chemotherapy for people with advanced HER2-negative stomach or gastroesophageal junction cancer. The study will enroll 64 participants who have not h…

This early-stage trial tests an experimental treatment called CBG131 for adults with advanced stomach or pancreatic cancer that has a specific marker (CLDN18.2). The therapy uses a patient's own immune cells, modified in a lab to target and attack cancer cells. The main goals are…

This phase 2 trial tests two different drug combinations given before surgery for people with a specific type of stomach cancer (dMMR/MSI-H). Participants will receive the immunotherapy drug adebrelimab plus either chemotherapy or another immunotherapy drug (SHR-8068). The goal i…

This study tests whether adding the drug ivonescimab to standard chemotherapy (SOX) can better shrink or eliminate tumors in people with locally advanced stomach or gastroesophageal junction cancer before surgery. About 154 adults aged 18-75 will be randomly assigned to receive e…

This study tests a new drug called JPI-547 combined with irinotecan for people with advanced stomach cancer that has come back or spread after at least two prior treatments. The goal is to see if the combination is safe and can shrink tumors. About 49 adults with good performance…

This study tests a new drug called IBI363, which helps the immune system attack cancer cells, combined with other drugs (bevacizumab with or without nab-paclitaxel) as a second treatment for people with advanced stomach cancer. About 50 adults aged 18-75 whose cancer worsened aft…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This study tests the drug Enhertu in 43 people with newly diagnosed HER2-positive stomach, esophageal, or gastroesophageal junction cancer that has spread. Participants have a lower physical ability (ECOG 2) and will receive Enhertu by IV every 3 weeks. The main goal is to see ho…

This phase 2 trial will test a combination of immunotherapy drugs and chemotherapy given before surgery for people with a specific genetic subtype of stomach cancer (dMMR/MSI-H). The study aims to see how well this approach clears the tumor and to understand why some patients do …

This study tests a treatment plan for people with stomach cancer that has spread to the lining of the abdomen. The plan combines heated chemotherapy directly in the abdomen (HIPEC), standard chemotherapy, and an immunotherapy drug called tislelizumab. The goal is to see if this c…

This study tests a new drug called TST001 added to standard chemotherapy and immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination helps control the tumor longer and improves surv…

This study tests a new drug called zanidatamab, given with chemotherapy before surgery, for people with a specific type of stomach or gastroesophageal junction cancer that has high levels of HER2 protein. The goal is to see if this combination can shrink tumors more effectively t…

This study tests whether a simple blood test that detects tiny traces of cancer DNA can guide treatment decisions after gastric cancer surgery. About 90 patients will have their blood tested after surgery, and those with no detectable cancer DNA may safely skip additional chemoth…

This study compares a new, less invasive surgery that removes only the cancerous upper part of the stomach to the standard full stomach removal. The goal is to see if the new approach helps patients lose less weight one year after surgery. The trial will enroll 120 adults with ea…

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This study tests two drugs, zanidatamab and tislelizumab, combined with standard chemo or radiation for people with HER2-positive stomach or colorectal cancers. About 70 adults aged 18-75 will receive the treatment to see if it shrinks tumors and controls the disease. The goal is…

This Phase 2 trial will test an experimental drug called SSGJ-706 combined with standard chemotherapy (and sometimes another drug, bevacizumab) in 300 people with advanced gastrointestinal cancers that cannot be surgically removed. The goal is to see if the combination is safe an…

This study is testing whether adding a probiotic called Lactobacillus johnsonii to standard chemotherapy and immunotherapy can help control advanced lung, breast, or stomach cancers. About 156 adults aged 18-75 will be randomly assigned to receive either the probiotic or a placeb…

This clinical trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy (albumin-bound paclitaxel) as a second-line treatment for advanced stomach or gastroesophageal junction cancer. The study will enroll 30 adults whose cancer has wor…

This study looks at 500 stomach cancer patients who had chemotherapy plus immunotherapy before surgery and achieved a complete response (no cancer left in the removed tissue). It compares different post-surgery treatments, including chemotherapy alone or with immunotherapy, to se…

This phase 2 trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and chemotherapy (SOX) in 20 people with a specific type of advanced stomach or gastroesophageal junction cancer (MSI-H/dMMR). The goal is to see if …

This study tests a new PET imaging tracer, [68Ga]Ga-NODAGA-SNA014, to detect a protein called Claudin18.2 in pancreatic and stomach cancers. The goal is to see if the scan can accurately identify patients whose tumors have this protein, which could help doctors choose the right t…

This study tests a new fluorescent dye that attaches to cancer cells, helping surgeons see exactly where a stomach tumor ends during surgery. The probe is tested on freshly removed stomach tissue from 32 patients. If successful, it could lead to more precise cancer removal and fe…

This study tests a new breath test to detect cancers of the stomach and esophagus. Participants provide a breath sample before and after drinking a special liquid. The test looks for chemicals in the breath that may signal cancer. The goal is to see if the drink makes these chemi…

This trial tests whether a home-based, digitally supervised prehabilitation program—using 5G and AI—can help gastric cancer patients get fitter before surgery. Participants who have completed chemotherapy and are scheduled for stomach removal will either receive standard care or …

This study tests whether a personalized, supervised exercise program done at home can improve physical function in people who have finished treatment for gastroesophageal cancer. About 20 survivors will receive tailored aerobic and resistance exercises via video calls. The goal i…

This study tests whether a drug called megestrol acetate can help prevent weight loss in people with stage III stomach cancer who are about to have surgery. About 48 participants will receive either standard treatment (chemoimmunotherapy) or standard treatment plus megestrol acet…

This observational study tracks how patients with stage II to IVB gastric or gastroesophageal junction cancer are actually treated in routine clinical practice across Greece. Researchers will collect data on patient characteristics, treatment choices, timing of therapies, and bio…

This study looks back at medical records from high-volume hospitals in Russia and China to compare how patients with stomach cancer or cancer at the junction of the stomach and esophagus fare after a specific surgery called proximal gastrectomy with double-tract reconstruction. R…

This study enrolls adults with stomach or gastroesophageal junction cancer who had a strong response to chemotherapy before surgery, with no or very little cancer left in the removed tissue. Researchers will use a personalized blood test that tracks tumor DNA to see if it can ide…

This study investigates why some stomach cancers do not respond to a standard chemotherapy combination (FLOT) plus the immunotherapy drug durvalumab. Researchers will analyze tumor samples and blood from 250 patients with operable stomach or gastroesophageal junction cancer. By m…

This study will follow 72 adults with early-stage gastroesophageal cancer to see how their physical function changes during chemotherapy. Participants will have their physical abilities measured at several points over six months. The goal is to understand which patients are at ri…

This study looks at whether emotional distress before treatment affects how well immunotherapy works in people with locally advanced stomach or gastroesophageal junction cancer. Researchers will measure distress using questionnaires and track tumor response after surgery. The goa…

This study looks at whether sleep patterns—like duration, quality, and heart rate during sleep—are linked to how well stomach cancer responds to immunotherapy before surgery. Researchers will monitor sleep non-invasively in 120 patients with locally advanced gastric or gastroesop…

This study looks at whether a tumor's DNA repair status (MMR) changes how well the presence of cancer cells in lymph vessels predicts spread to lymph nodes in stomach cancer. Researchers will review medical records of 3,000 patients who had surgery. The goal is to improve risk as…

This study tests whether a personalized blood test (Signatera) can identify gastric cancer patients who, after surgery, have no detectable cancer DNA and can safely receive a milder immunotherapy (durvalumab) instead of standard chemotherapy. About 1000 adults with stage II-IVa g…

This study looks at whether a simple blood test can help doctors decide the best treatment after surgery for stomach or gastroesophageal junction cancer. About 32 people with stage III or IVA cancer will give blood samples before and after surgery to check for tumor DNA. The goal…

This study looks at whether sharing genetic risk information with Barrett's esophagus patients can improve their quality of life and reduce cancer worry. Researchers will collect tissue samples and use genetic analysis to create risk profiles. Half of the 266 participants will le…